INHIBITION AND INDUCTION OF DRUG-METABOLISM BY PSORALENS - ALTERATIONS IN DURATION OF SLEEP INDUCED BY HEXOBARBITAL AND IN CLEARANCE OF CAFFEINE AND HEXOBARBITAL IN MICE

被引:7
作者
APSELOFF, G
HILLIARD, JB
GERBER, N
MAYS, DC
机构
[1] Department of Pharmacology, College of Medicine, Ohio State University, Columbus, OH
关键词
D O I
10.3109/00498259109044396
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Hexobarbital (100 mg/kg i.p.) sleeping times in male CD-1 mice pretreated (-1 h) with a single i.p. injection of 150-mu-mol/kg of psoralen or coumarin analogues were increased, most markedly (6-fold) by linear, methoxy-substituted psoralens. 2. Hexobarbital sleeping times of mice which received three daily injections (231-mu-mol/kg; 50 mg/kg) of 8-methoxypsoralen (8-MOP) were 44% of controls (corn oil). 3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively. 4. The whole-body concentrations of hexobarbital (100 mg/kg dose) in mice 30 min after dosing were 14.3 +/- 0.9, 8.4 +/- 0.3, and 5.2 +/- 0.5-mu-g/ml (1 mouse = 150 ml) following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively. 5. It is concluded that, administered acutely, psoralen analogues inhibit hexobarbital metabolism in mice; and 8-MOP administered acutely inhibits the metabolism of caffeine and hexobarbital, but administered repeatedly increases their metabolism.
引用
收藏
页码:1461 / 1471
页数:11
相关论文
共 32 条
[11]   TREATMENT OF CUTANEOUS T-CELL LYMPHOMA BY EXTRACORPOREAL PHOTOCHEMOTHERAPY - PRELIMINARY-RESULTS [J].
EDELSON, R ;
BERGER, C ;
GASPARRO, F ;
JEGASOTHY, B ;
HEALD, P ;
WINTROUB, B ;
VONDERHEID, E ;
KNOBLER, R ;
WOLFF, K ;
PLEWIG, G ;
MCKIERNAN, G ;
CHRISTIANSEN, I ;
OSTER, M ;
HONIGSMANN, H ;
WILFORD, H ;
KOKOSCHKA, E ;
REHLE, T ;
PEREZ, M ;
STINGL, G ;
LAROCHE, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (06) :297-303
[12]  
FOUINFORTUNET H, 1986, J PHARMACOL EXP THER, V236, P237
[13]   THE TURNOVER OF CYTOCHROME P450B [J].
GASSER, R ;
HAURI, HP ;
MEYER, UA .
FEBS LETTERS, 1982, 147 (02) :239-242
[14]  
GERBER N, 1971, J PHARMACOL EXP THER, V177, P234
[15]   SUCCESSFUL TREATMENT OF THE PRURITUS OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTION AND ACQUIRED IMMUNODEFICIENCY SYNDROME WITH PSORALENS PLUS ULTRAVIOLET-A THERAPY [J].
GORIN, I ;
LESSANALEIBOWITCH, M ;
FORTIER, P ;
ESCANDE, JP .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1989, 20 (03) :511-513
[16]  
GOUJON FM, 1972, MOL PHARMACOL, V8, P667
[17]  
HILLIARD JB, 1987, FASEB J, V46, P863
[18]  
HOLCOMB R R, 1974, Journal of Pharmacology and Experimental Therapeutics, V188, P15
[19]  
LABBE G, 1989, J PHARMACOL EXP THER, V250, P1034
[20]   METABOLIC REACTIONS INVITRO OF PSORALENS WITH LIVER AND EPIDERMIS [J].
MANDULA, BB ;
PATHAK, MA .
BIOCHEMICAL PHARMACOLOGY, 1979, 28 (01) :127-132